ストックスクリーナーアプリを入手
5.4568
2.35%
0.1268
Savara Inc (SVRA) 最新ニュース
SVRA|Savara Inc|Price:5.435|Chg%:-0.075 - TradingKey
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Institutional Confidence - TradingKey
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Savara Inc (SVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara, Inc. Revenue Breakdown – NASDAQ:SVRA - TradingView
TradingKey - TradingKey
SVRA|Savara Inc|Price:5.510|Chg%:-0.240 - TradingKey
Form 4 Savara Inc For: 24 July By Investing.com - Investing.com Nigeria
Savara Inc. CFO Robert Lutz Secures 70,000 Stock Options and 35,000 RSUs in Insider Transaction - Kalkine Media
Savara Inc (NASDAQ: SVRA) grants CFO 70,000 options, 35,000 RSUs - Stock Titan
Savara Inc. (SVRA) Edges Lower as Stock Approaches Critical Support at $5.37Demand Zone - dars.gov.et
SVRA Q1 2026 Earnings: Wider-than-Expected Loss Amidst Ongoing Clinical DevelopmentEarnings Revision Upgrade - dars.gov.et
Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
ETFs Investing in Savara, Inc. Stocks - TradingView
Savara stock gains as Phase 3 data support FDA review of inhaled lung therapy - Ad-hoc-news.de
If You Invested $1,000 in Savara Inc (SVRA) - Stock Titan
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Here's Why You Should Add Savara Stock to Your Portfolio Now - Yahoo Finance
SVRA Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Company Continues Clinical ProgressEarnings Power Value - dars.gov.et
What Does the FDA's Priority Review Mean for Savara's MOLBREEVI - Kavout | AI
SVRA Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue StageEarnings Revision Upgrade - dars.gov.et
Join Class Action to Recover Losses from Savara Inc. (SVRA)Contact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - AOL.com
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 20 - AOL.com
Savara stock. Thin-source profile holds the focus. - ad-hoc-news.de
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Commercial Spending RampsOne-Time Gain Impact - dars.gov.et
Enterprise value to EBIT forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Enterprise value to EBITDA forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Price to earnings forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc focuses on respiratory drug development as investors watch clinical progress - Ad-hoc-news.de
Price to book forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Price to sales forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Enterprise value to revenue forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline - The National Law Review
SVRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Development AdvancesGrowth Acceleration Report - dars.gov.et
Securities Lawsuit Alert: Savara Inc. (SVRA) InvestorsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline - The National Law Review
SVRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Levi & Korsinsky Notifies Savara Inc. (SVRA) InvestorsLead Plaintiff Deadline on November 7, 2025 - The National Law Review
Investors SueWallSt as Savara Inc. Faces Securities Fraud Allegations - The National Law Review
Investors in Savara Inc. (SVRA): Protect Your RightsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline - AOL.com
Savara, Inc. Actuals & Estimates (FWB:YB4P) - TradingView
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
Savara, Inc. Actuals & Estimates (SWB:YB4P) - TradingView
YB4P Forecast — Price Target — Prediction for 2027 - TradingView
Savara CFO David Lowrance sells $2.24m in company stock By Investing.com - Investing.com Nigeria
Savara CFO David Lowrance sells $2.24m in company stock - Investing.com UK
Form 4 Savara Inc For: 22 June By Investing.com - Investing.com Nigeria
2.55%
3.84%
大文字化:
|
ボリューム (24 時間):